June 8, 2020 — As the QuartzBio team’s efforts have progressed with the selection and integration of SARS-CoV-2 / COVID-19 data sets, I am pleased to share our first public update on analysis. This work builds on an evaluation of IFN-α2b treatment, and supports the rationale that interferons are upregulated as part of the antiviral defense, specifically for COVID-19. We are also sharing this work as a demonstration of the potential for translational research and drug repurposing while mitigating the time, expense, and reproducibility challenges inherent in drug/treatment combination discovery. This need for speed and flexibility is, of course, at the top of our minds as we respond to the global pandemic.

Read more